Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Go back to Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 217.13 +1.12 (0.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $216.01 | 52 Week High | $333.65 | |||
| Open | $216.91 | 52 Week Low | $223.02 | |||
| Day High | $217.68 | P/E | 27.80 | |||
| Day Low | $216.15 | EPS | $7.81 | |||
| Volume | 14,029 | |||||
| (NASDAQ: IONS) | Delayed: 46.38 +1.54 (3.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.84 | 52 Week High | $62.68 | |||
| Open | $46.63 | 52 Week Low | $19.59 | |||
| Day High | $47.42 | P/E | N/A | |||
| Day Low | $46.34 | EPS | $0.00 | |||
| Volume | 124,049 | |||||
